Category News

Aya Locums

Aya Locums Physician Assistant Recognized as a 2025 Locum Tenens Provider of the Year by Locumpedia

Aya Locums’ Physician Assistant Named a “2025 Locum Tenens Providers of the Year” by Locumpedia Locumpedia named Alain Raymond, PA-C, a cardiothoracic surgical physician assistant with Aya Locums and a U.S. Navy veteran, as a “2025 Locum Tenens Providers of…

Read MoreAya Locums Physician Assistant Recognized as a 2025 Locum Tenens Provider of the Year by Locumpedia
Hims & Hers

Hims & Hers Introduces Multi-Cancer Early Detection Testing to Expand Access to Proactive Preventive Care

Hims & Hers Launches Multi-Cancer Early Detection Testing, Connecting Customers to Cutting-Edge Proactive Care Today, Hims & Hers Health, Inc. (NYSE: HIMS), the leading digital health and wellness platform, launched access to the Hims & Hers Multi-Cancer Test by Galleri®,…

Read MoreHims & Hers Introduces Multi-Cancer Early Detection Testing to Expand Access to Proactive Preventive Care
Clarest Health

Clarest Health Launches “Clarest at Home” to Improve Medication Continuity from Facility to Home

Clarest Health Launches “Clarest at Home,” Closing the Gap in Medication Management from Facility to Front Door Clarest Health, a leader in personalized medication management, announced the launch of Clarest at Home, a comprehensive at-home medication care solution. This offering is…

Read MoreClarest Health Launches “Clarest at Home” to Improve Medication Continuity from Facility to Home

Johnson & Johnson Showcases New Scientific Evidence and Strengthens Leadership Through Portfolio Innovations at AF Symposium

Johnson & Johnson Showcases New Scientific Evidence and Strengthens Leadership Through Portfolio Innovations at AF Symposium Johnson & Johnson is announcing new portfolio innovations in addition to compelling clinical evidence in atrial fibrillation (AFib) at the 31st Annual AF Symposium in Boston.…

Read MoreJohnson & Johnson Showcases New Scientific Evidence and Strengthens Leadership Through Portfolio Innovations at AF Symposium

EYLEA HD® 8 mg Data at Angiogenesis 2026 Highlight Robust Retinal Disease Profile

EYLEA HD® (aflibercept) 8 mg Data Presented at Angiogenesis 2026 Highlight Robust Clinical Profile in Treating Serious Retinal Diseases Regeneron Pharmaceuticals, Inc. today announced upcoming presentations from its ophthalmology portfolio and pipeline at the virtual Angiogenesis (Angiogenesis, Exudation, and Degeneration)…

Read MoreEYLEA HD® 8 mg Data at Angiogenesis 2026 Highlight Robust Retinal Disease Profile
Johnson & Johnson

CHMP Grants Positive Opinion for AKEEGA® in BRCA1/2-Mutated mHSPC

Johnson & Johnson Secures CHMP Positive Opinion for AKEEGA®—a Dual-Action Tablet Combining Niraparib and Abiraterone Acetate—for Treating Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in Patients with BRCA1/2 Mutations Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use…

Read MoreCHMP Grants Positive Opinion for AKEEGA® in BRCA1/2-Mutated mHSPC

WuXi Biologics and Sinorda Biomedicine Forge Strategic Alliance to Advance Bispecific Antibody Development and Manufacturing

WuXi Biologics and Sinorda Biomedicine Forge Strategic Partnership to Advance Development and Manufacturing of Innovative Bispecific Antibodies WuXi Biologics, a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), and Sinorda Biomedicine today jointly announced a strategic collaboration for the…

Read MoreWuXi Biologics and Sinorda Biomedicine Forge Strategic Alliance to Advance Bispecific Antibody Development and Manufacturing
Intellia

Intellia Therapeutics Announces FDA Lifts Clinical Hold on MAGNITUDE-2 Phase 3 Trial for ATTRv-PN

Intellia Therapeutics Announces FDA Lifts Clinical Hold on MAGNITUDE-2 Phase 3 Trial for ATTRv-PN Intellia Therapeutics, Inc., a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S. Food and Drug Administration (FDA) has removed…

Read MoreIntellia Therapeutics Announces FDA Lifts Clinical Hold on MAGNITUDE-2 Phase 3 Trial for ATTRv-PN
BioMarin

BioMarin Announces Proposed Private Offering of Senior Notes and Launch of New Senior Secured Term Loan Facility

BioMarin Moves to Strengthen BalanceBioMarin Announces Proposed Private Offering of Senior Notes and New Senior Secured Term Loan Syndication BioMarin Pharmaceutical Inc. announced today that it intends to offer, subject to market and other conditions, $850 million of senior unsecured…

Read MoreBioMarin Announces Proposed Private Offering of Senior Notes and Launch of New Senior Secured Term Loan Facility
Aspect

Aspect Biosystems and Novo Nordisk Advance Partnership to Develop Curative Therapies for Diabetes

Aspect Biosystems and Novo Nordisk Advance Partnership to Develop Curative Diabetes Therapies Novo Nordisk and Aspect Biosystems today announced they are entering a new phase of their partnership to develop advanced cellular medicines for diabetes. Since 2023, Aspect andNovo Nordisk…

Read MoreAspect Biosystems and Novo Nordisk Advance Partnership to Develop Curative Therapies for Diabetes
Bristol

Bristol Myers Squibb Partners with Microsoft to Accelerate AI-Powered Early Lung Cancer Detection

Bristol Myers Squibb Teams Up with Microsoft to Accelerate AI-Powered Early Lung Cancer Detection Bristol Myers Squibb, a global leader in oncology, today announced an agreement with Microsoft, a market leader in AI-powered radiology and clinical workflow technologies, aiming to…

Read MoreBristol Myers Squibb Partners with Microsoft to Accelerate AI-Powered Early Lung Cancer Detection